Lamivudine and Dolutegravir
- Generic Name
- Lamivudine and Dolutegravir
- Indication
用于治疗感染人类免疫缺陷病毒1型(HIV-1)的成人和12岁以上青少年（体重至少40kg），且对整合酶抑制剂或拉米夫定无已知或可疑耐药患者。
Good-first: B/F/TAF As First-line ART
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 630
- Registration Number
- NCT06619288
- Locations
- 🇨🇳
Nantong Third Peoples Hospital, Nantong, Jiangsu, China
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Saskatchewan Health Authority - Regina Area
- Target Recruit Count
- 40
- Registration Number
- NCT06580873
- Locations
- 🇨🇦
Saskatchewan Health Authority, Regina, Saskatchewan, Canada
B/F/TAF to DTG/3TC Switch Study
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Nairobi
- Target Recruit Count
- 240
- Registration Number
- NCT06444620
- Locations
- 🇰🇪
Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya
🇰🇪Kenyatta National Hospital, Nairobi, Kenya
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 171
- Registration Number
- NCT05917509
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 206
- Registration Number
- NCT05911360
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 84
- Registration Number
- NCT05549180
- Locations
- 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain
🇪🇸CHUAC, Coruña, Spain
🇪🇸Hospital Universitario La Princesa, Madrid, Spain
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Societa' Italiana Di Malattie Infettive E Tropicali
- Target Recruit Count
- 440
- Registration Number
- NCT04979468
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Policlinico di Bari, Bari, BA, Italy
🇮🇹ASST Papa Giovanni XXIII, Bergamo, BG, Italy
🇮🇹ARNAS Garibaldi, Catania, CT, Italy
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 33
- Registration Number
- NCT04827134
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.